The term “subclinical HPP” has been coined to describe clinically asymptomatic individuals with both genetic features (ALPL variant and/or positive family history) and the biochemical signature of HPP (i.e., low ALP activity with one or more elevated substrates: PLP, PEA, or PPi). The gene discussed is ALPL; the disease is hypophosphatasia.